JANESVILLE, Wis., June 6, 2024 /PRNewswire/ -- SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals. SHINE has provided the first supply of Ilumira – its non-carrier added lutetium-177 (n.c.a. Lu-177) chloride – to Blue Earth Therapeutics that will be used in clinical trials to assess a potential treatment for men with prostate cancer. This partnership follows SHINE's submission of a Drug Master File to the U.S. Food and Drug Administration – enabling SHINE to be on a fast track to deliver for its customers.
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
Blue Earth Announces Participation in Upcoming B. Riley Investor Conference
Blue Earth Announces Publication of Results from Experience with 177Lu-rhPSMA-10.1
Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer
MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 by the Company and a collaborator at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 24 – 27, 2023. 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical for the treatment of prostate cancer. The presentations included results from an independent clinical study conducted by the University of Augsburg that investigated dosimetry and the therapeutic index for 177Lu-rhPSMA-10.1. Also being presented are results of Blue Earth Therapeutics’ preclinical studies that examined the therapeutic dose response of 177Lu-rhPSMA-10.1 and the therapeutic efficacy of 177Lu-rhPSMA-10.1 as compared to several other compounds. 177Lu-rhPSMA-10.1 is the first clinical candidate in Blue Earth Therapeutics’ oncology development program of advanced targeted therapeutic radiopharmaceuticals. An investigational Phase 1/2 clinical trial (NCT05413850) evaluating the safety, tolerability, dosimetry and anti-tumor activity of 177Lu-rhPSMA-10.1 in eligible men with metastatic castrate-resistant prostate cancer (mCRPC) is underway in the United States.
MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced upcoming presentations by the Company and a collaborator at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 24 – 27, 2023 in Chicago, Ill. Presentations on investigational clinical and preclinical studies of therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology are being made at the conference. They include early clinical experience and a preclinical evaluation of 177Lu-rhPSMA-10.1, currently being investigated by Blue Earth Therapeutics as a potential PSMA-targeted therapeutic radiopharmaceutical candidate for the treatment of prostate cancer.
Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)